OpenAI misses growth targets before IPO push

/in /tarafından

OpenAI has reportedly fallen short of internal revenue and user growth goals as it prepares for a potential IPO, according to the Wall Street Journal.

The report says ChatGPT user growth slowed late last year, missing a target of 1 billion weekly active users, while revenue also underperformed projections amid stronger competition from Anthropic in coding and enterprise AI markets.

CFO Sarah Friar reportedly raised concerns internally about whether slower growth could challenge OpenAI’s ability to sustain massive future data-center and computing commitments. Subscriber churn has also reportedly increased.

CEO Sam Altman and Friar publicly rejected suggestions of internal misalignment, stating the company remains focused on securing compute capacity and expanding aggressively.

EU pressures Google to open Gemini and Android AI access

/in /tarafından

The European Commission has outlined new measures requiring Google to give rival AI developers and search competitors broader access to Android features and services linked to Gemini under the Digital Markets Act (DMA).

The proposal aims to let competing AI assistants better integrate with Android devices, including sending emails, sharing content, ordering services and interacting with apps without Google prioritizing Gemini.

EU regulators say this would expand user choice and reduce platform favoritism. Google argues the move could weaken privacy, security and manufacturer flexibility by forcing access to sensitive device functions.

Third parties can submit feedback until May 13, with a final EU ruling expected by late July. Non-compliance could lead to fines of up to 10% of global annual revenue.

J&J says AI cuts drug lead development time in half

/in /tarafından

Johnson & Johnson says artificial intelligence is reducing by 50% the time needed to generate early drug development leads, accelerating how quickly promising compounds are identified.

According to J&J, AI is helping screen large pools of chemical and biologic candidates faster, improving lead optimization in areas such as cancer and immunology. The company says it has already sped up development for two compounds.

AI is also transforming operations beyond discovery:

  • Clinical trial documentation reduced from hundreds of hours to minutes
  • Faster patient recruitment
  • Improved manufacturing efficiency
  • Enhanced surgical precision in medical devices

J&J says AI is not yet replacing full drug discovery, but it is becoming a major force multiplier in speeding research, regulatory workflows and treatment innovation.